Clinical trials: Huntington's Disease (HD)
Huntington Disease
Effect of Tetrabenazine on Stroop Interference in HD
Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing.
- Trial name
- NCT01834911
- Testing
- Tetrabenazine withdrawal
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- New York Medical College
Huntington Disease
Extracellular Vesicles for HD
The primary objective of this study is to discover blood-based biomarker of brain Huntingtin (HTT) protein using extracellular vesicles to be used in evaluating target engagement in HTT lowering clinical trials.
- Trial name
- NCT06082713
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Central Florida
Huntington Disease
Evaluation of Three Tests to Assess Social Cognition in Huntington Disease
The goal of this observational study is to learn about the usefulness of a test of social functioning in persons with Huntington disease.
- Trial name
- NCT07253038
- Where
- Sweden
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Region Skane
Huntington Disease
IMarkHD: in Vivo Longitudinal Imaging of HD Pathology
iMarkHD is an adaptive, longitudinal positron emission tomography (PET) and magnetic resonance (MR) imaging study in Huntington's disease (HD) that aims to assess abnormal molecular, functional, and structural changes in…
- Trial name
- NCT03434548
- Testing
- PET imaging, Multi-modal MRI imaging
- Where
- United Kingdom
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- King's College London
Huntington's Disease (HD)
Creatine Safety & Tolerability in Huntington's Disease
The purpose of this study is to extend findings from the creatine dose-finding study (CREST-UP1) in Huntington's disease to evaluate the long-term safety, tolerability, and clinical impact of high dose creatine.
- Trial name
- CREST-X (NCT01412151)
- Testing
- Creatine monohydrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Huntington Disease
A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease
A Phase I/II Dose-Finding Study to Evaluate Striatal Administration of AB-1001 (previously BV-101) in Adults with Early Manifest Huntington's Disease
- Trial name
- NCT05541627
- Testing
- AB-1001 Gene Therapy
- Where
- France
- Volunteers
- 5 people
- Sponsor
- AskBio France, SAS, a subsidiary of AskBio Inc.
Huntington Disease
Longitudinal SV2A PET and MRI in Premanifest HD
AIM: to compare the sensitivity of SV2A PET and volumetric MRI to detect longitudinal striatal changes in premanifest HD. DESIGN: The investigators will include late premanifest HD mutations carriers and matched healthy controls.
- Trial name
- NCT06626412
- Testing
- Diagnostic Test: 18F-SynVesT-1 PET, Volumetric MRI
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Huntington's Disease
Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease
Huntington's Disease (HD) is an autosomal dominant disease manifested in a triad of cognitive, psychiatric, and motor signs and symptoms. HD is caused by a triplet repeat (CAG)expansion in the gene Huntingtin (HTT).
- Trial name
- ChANGE HD (NCT01860339)
- Where
- 6 sites in United States
- Volunteers
- 488 people, healthy volunteers welcome
- Sponsor
- Peggy C Nopoulos
Huntington's Disease
Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD
This study will examine the ways in which people reveal their status as a carrier of Huntington s disease (HD) or of being at risk for the disease.
- Trial name
- NCT00491842
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Huntington Disease
Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease
Cellavita HD is a stem-cell therapy for Huntington's Disease. This is a prospective, phase II, single-center, randomized (2:2:1), triple-blind, placebo controlled study, with two test doses of Cellavita HD product.
- Trial name
- ADORE-DH (NCT03252535)
- Testing
- Cellavita HD lower dose, Cellavita HD higher dose
- Where
- Brazil
- Volunteers
- 49 people
- Sponsor
- Azidus Brasil
Huntington Disease
The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease
The goal of this clinical trial is to learn if oral supplement of nicotinamide riboside (NR), a form of vitamin B3, slows disease progression in adults with Huntington's disease.
- Trial name
- NAD-HD (NCT06853743)
- Testing
- Nicotinamide Riboside (NR)
- Where
- Norway
- Volunteers
- 120 people
- Sponsor
- Oslo University Hospital
Huntington's Disease
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
The primary objective of this study is to assess the efficacy of laquinimod as treatment in participants with HD after 52 weeks using the Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS-TMS or TMS).
- Trial name
- LEGATO-HD (NCT02215616)
- Testing
- Laquinimod
- Where
- 53 sites in United States, Canada and 8 more
- Volunteers
- 352 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Huntington's Disease
Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease
This study will examine whether lithium carbonate, given alone or with divalproex, increases the amount of brain-derived neurotrophic factor (BDNF) in the spinal fluid of patients with Huntington's disease (HD), a hereditary…
- Trial name
- NCT00095355
- Testing
- Lithium, Divalproex
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)